MedElevator Войти в исследования
← Поиск публикаций

DOI 10.32598/bcn.2024.4970.1

Медицинская библиотека · Basic and clinical neuroscience · 2025

Short-term Efficacy of Commercial Curcumin Nanomicelle on Cognition, Oxidative Stress and Choline Esterase in Alzheimer's Disease.

Kazemi Samira, Hesni Langroudi Narges, Hasani Abharian Peyman, Tavakol Kamran, Joghataei Mohammad Taghi, Tavakol Shima, Arbabi Bidgoli Sepide

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by cognitive dysfunction. Preclinical changes can precede the onset of clinical symptoms by decades, highlighting the need for preventative and therapeutic strategies to mitigate or delay disease progression. This pilot clinical trial aimed to investigate the effects of commercially available curcumin nanomicelles on oxidative stress pathways and serum cholinesterase levels in patients with AD.

METHODS

Fifteen volunteers with mild-to-severe AD and 15 age-matched healthy controls were enrolled. Participants with AD received 80 mg of thermodynamically stable 10 nm curcumin nanomicelles on alternate days for two months. Cognitive function, as assessed by the mini-mental state examination (MMSE), did not exhibit significant changes in patients with AD following curcumin nanomicelle administration (19.8 versus 20.6). Serum levels of oxidative stress biomarkers, including catalase (CAT), superoxide dismutase (SOD) inhibition, malondialdehyde (MDA) concentration, and cholinesterase activity, were evaluated before and after intervention.

RESULTS

The results showed no significant differences in cognition improvement, CAT activity, SOD inhibition, MOD concentration, or cholinesterase activity between patients with AD and healthy controls or before and after curcumin nanomicelle administration.

CONCLUSION

Although curcumin nanocarriers did not enhance antioxidant biomolecule levels, they did not provoke lipid peroxidation. Therefore, this study suggests that optimizing nanocarrier parameters, including concentration, particle size larger than 10 nm, and blood-brain barrier (BBB)targeting, warrants further investigation in a long-term study to explore their potential as supplemental therapies for AD.

Для цитирования: Kazemi Samira, Hesni Langroudi Narges, Hasani Abharian Peyman, Tavakol Kamran, Joghataei Mohammad Taghi, Tavakol Shima, Arbabi Bidgoli Sepide. Short-term Efficacy of Commercial Curcumin Nanomicelle on Cognition, Oxidative Stress and Choline Esterase in Alzheimer's Disease.. Basic and clinical neuroscience. 2025. DOI: 10.32598/bcn.2024.4970.1.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.